Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. - Wikidata - awgldk - TriplyDB

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

http://www.wikidata.org/entity/Q37011627

about

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs Clinical potential of pacritinib in the treatment of myelofibrosis IRAK signalling in cancer Role of microRNA-146a in normal and malignant hematopoietic stem cell function IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance Deconstructing innate immune signaling in myelodysplastic syndromes Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes The Role of Toll-Like Receptors in Hematopoietic Malignancies Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.Errant innate immune signaling in del(5q) MDS.An MDS xenograft model utilizing a patient-derived cell line.Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma.Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome.Regulation of stress-induced hematopoiesis Biology of the bone marrow microenvironment and myelodysplastic syndromes.IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.Targeting IRAK1 in T-cell acute lymphoblastic leukemia Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma.Induction of myelodysplasia by myeloid-derived suppressor cells.Stem cell origin of myelodysplastic syndromes.IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.The inflammatory microenvironment in MDS.Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.Pacritinib: a new agent for the management of myelofibrosis?β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.Stem and progenitor cell alterations in myelodysplastic syndromes.The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.Inflammation: a key regulator of hematopoietic stem cell fate in health and disease.The study of homology between tumor progression genes and members of retroviridae as a tool to predict target-directed therapy failure.Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

P2860

Q26744481-D37906C8-3033-45F3-8A6A-C05BE3B517FA Q26766039-737C1F28-978B-4F0D-820B-47D4853303C8 Q26796450-A8B4BEE8-8895-4A7A-8C53-84A068009A4B Q26863735-84A8B186-FCA2-426A-8CD1-FF2FAE819BAA Q26864607-8694E727-CB29-4E3A-A186-C5EF0BBB1FA6 Q26866390-8CE3C9EE-FC95-4504-B29E-A5002352747A Q26991974-D91BC89A-214B-4C70-A95D-871C75111BB4 Q27015288-E9141DFB-4756-4E8A-AB31-B6FA8CF57CEA Q28077740-DE17373B-87CE-48BF-AD53-4EA407EC5D71 Q33652652-3C9BC149-D686-4BAB-8A1F-4E3D8857C95B Q33987039-0800AFF6-43B2-472A-B80C-0DCDFEB29198 Q34433095-6B97C645-69DC-4F9F-92A5-6108384B1722 Q34480968-4E10402E-0579-4E0C-824D-351A445BCD3D Q34540749-D84B851B-0A2F-48A5-9280-109C24E60D81 Q35183900-586F2CFC-E575-4B34-80B1-DEAA7F89A4FB Q35607293-0C53E7EC-58C9-4124-B731-EEF1FCC6C51A Q35803662-C3FB0D2A-E4CE-4DD2-AEF3-D9EC1BF9BD8B Q35866423-79A82C57-CC4D-4AD3-B538-DF7B22B5EFC7 Q36069153-E1EFBD71-324B-43B6-924F-6A29E1516D17 Q36201068-66CF02A8-E89E-4938-A23F-65CD1D7BD28D Q36266768-39CF1FB5-9926-4E3A-8974-FC19F984ECC3 Q36326296-9890602C-5BD6-44FD-9761-2C72E1532E0B Q36327564-DAE06B00-5695-4375-AD05-5FF8A386A843 Q36909178-0C2CF2EF-16F6-4577-AF6D-5578607DB093 Q37014078-C9C96DDF-70CA-4BB7-9FEB-44F1C8FB472F Q37251454-338B7663-4F01-47D7-B8E5-0EDBF8691F0B Q37259216-B79AF3D6-6E1E-4415-AA19-F06D604C15CD Q38171230-7A033800-253C-4718-A33A-2314F74986F3 Q38295578-FC0FCA33-125C-45AE-B392-79AFAF99DCCA Q38348119-A388B6B1-6AC8-4DE3-96A5-E9D7A1B30E68 Q38571471-D4B59CC6-EC50-48CB-92C8-22C15DEE19D9 Q38590232-9352D925-F345-4F1A-B50C-2E1FA2AF1222 Q38727081-C8592BD0-39E8-4247-B0F6-6C6ECCBE3036 Q38747542-6499E980-01F6-4FA7-B868-A6C832797496 Q38761791-615DBCC3-2267-43FB-B832-0AD8A31FAAB7 Q38951695-3DD1E87D-1622-406E-9E7D-43931DAE3456 Q39323428-D5751B09-1532-4B6E-AC2C-C8D343FA1037 Q40066012-8FB566F2-3930-4ABB-B6B7-95B94E9093F1 Q40151542-9579B1F7-FCAC-4612-A3F8-D870A96A4F77 Q41448224-3C516F2E-D57A-4713-B039-0D25AE85A9AC

P2860

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

http://www.wikidata.org/entity/Q37011627

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

@en

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

@nl

type

label

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

@en

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

@nl

prefLabel

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

@en

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

@nl

P1433

Q37011627-9E267514-DFB5-41D0-8480-5429109B04F4

P1476

Q37011627-D68E9B23-AB86-4E82-9DE7-7D9BBD81593B

P2093

Q37011627-02029661-3736-489E-B919-AC3ACF4D97D8

Q37011627-043D9EC2-904F-4EC9-925B-83DB6B7F1231

Q37011627-130E8FE0-7AC2-4A41-9BAD-D290D04AA848

Q37011627-1A509108-6674-4DB2-8F12-2D19CE752B55

Q37011627-20D22BB4-51EE-4F73-B76C-627528B2BF8D

Q37011627-28F14063-2CEC-4F57-B056-00851082007B

Q37011627-2929CD7A-1E04-4CB7-BF3F-795FECBE9DD7

Q37011627-43BFB21F-BCBA-40B8-ADBF-45DC17152AAB

Q37011627-5188EDA6-8323-413F-BA79-AEEA02819420

Q37011627-5348D39C-296F-414E-8B16-7CB00EE425FB

P2860

Q37011627-0362BCC2-B8E2-4656-A3E0-80A91D1C70D1

Q37011627-0A5B8241-B421-4AA0-859B-C0EDABDE53DB

Q37011627-0D6CDF82-A848-45E9-8646-C6C479A8D909

Q37011627-0D7BA55A-3569-4545-938F-BDA3FF618F7C

Q37011627-11900D9D-F741-47C1-B898-F9DFCE1C3FB9

Q37011627-3B64F847-312F-4ED1-9875-3A2572EFEE14

Q37011627-4391D830-3CE3-4F5B-8B55-7E55BD31D49A

Q37011627-49AC27A0-C4CA-47FA-86F9-E21B319E7BF1

Q37011627-4E0D1D3E-99B1-4966-9E43-EF4902DAB0D4

Q37011627-5774343E-0B00-410B-834E-CB9451CED01B

P304

Q37011627-6D54255A-34FE-4269-A727-ACBB5C2FC7D6

P31

Q37011627-B3282AD5-029D-4631-AE3F-9EFE957C7C02

P356

Q37011627-80B58FF3-E449-4F44-B790-D45D833E04E3

P433

Q37011627-444DB2E0-A8DE-429C-8DC7-576D01AC3937

P478

Q37011627-F61A4D82-718E-453C-B335-861E10D5E690

P50

Q37011627-6231FB2E-FBE2-4393-8A92-041F4E965516

Q37011627-F6911ADF-CFDF-4B89-9591-1F2F32FDB0D2

P577

Q37011627-7BE0C2F8-E12F-4074-93E9-0AF7BBD4CDED

P5875

Q37011627-60E6F981-9E3A-4F26-BF70-E09BC80EAEB4

P698

Q37011627-EAF74D57-8BE6-4A14-9F4B-03CFF6A8B3BC

P932

Q37011627-9D6A5467-2F6D-4E20-A0FD-A83B7A78BEBA

P356

J.CCR.2013.05.006

P1433

P1476

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

@en

P2093

Andres Jerez

http://www.w3.org/2001/XMLSchema#string

Carmela Rigolino

http://www.w3.org/2001/XMLSchema#string

Craig Thomas

http://www.w3.org/2001/XMLSchema#string

Daniel T Starczynowski

http://www.w3.org/2001/XMLSchema#string

Esther N Oliva

http://www.w3.org/2001/XMLSchema#string

Garrett W Rhyasen

http://www.w3.org/2001/XMLSchema#string

James C Mulloy

http://www.w3.org/2001/XMLSchema#string

Jaroslaw P Maciejewski

http://www.w3.org/2001/XMLSchema#string

Jing Fang

http://www.w3.org/2001/XMLSchema#string

Jonathan Keller

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice

Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses

IRAK-4 inhibitors for inflammation

Oncogenically active MYD88 mutations in human lymphoma

International scoring system for evaluating prognosis in myelodysplastic syndromes

Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.

AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3.

P304

90-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2013.05.006

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Agostino Cortelezzi

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

248704645

http://www.w3.org/2001/XMLSchema#string

P698

23845443

http://www.w3.org/2001/XMLSchema#string

P932

3711103

http://www.w3.org/2001/XMLSchema#string